Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares
Main finding · Newly initiated on ULTResult — go to the resultAdjusted odds ratio 11.5 95% CI 4.36–30.5Authors' conclusion
Over 90% of patients were initiated on ULT after implementing a strategy to optimize hospital gout care. Despite increased initiation of ULT during flares, recurrent hospitalizations were not more frequent following implementation.
Study context
- Population
- Patients hospitalized for gout flares94 and 97 with 6-month follow-up
- Exposure
- Post-implementation vs pre-implementation
- Outcome
- New ULT initiation
- Follow-up
- 6 months
Methodological detailspre-post implementation comparison with retrospective cohort
- Pre-post implementation comparison with retrospective cohort
Main finding
Newly initiated on ULT
Adjusted odds ratio
11.5
95% CI 4.36–30.5
P < 0.001
By group
Post-implementationvs Pre-implementation
aOR 11.5 (95% CI 4.36–30.5); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Pre-implementation | Post-implementation | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Serum urate ≤360 μmol/l · within 6 months of discharge | 10.6% | 26.8% | 3.04 (1.36–6.78) | P = 0.007 | |
| 0.10.31310Adjusted odds ratio (log scale) |
Safety
| Outcome | Pre-implementation | Post-implementation | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Re-hospitalized for flares | 14.9% | 9.3% | 0.53 (0.22–1.32) | P = 0.18 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares. Rheumatology (Oxford). Published 31 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →